(Q39342330)

11 September 2017

0 references

Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents (English)

1 reference

11 September 2017

1 reference

1 reference

Robert Bettis

1

1 reference

11 September 2017

Dominick Iacuzio

2

1 reference

11 September 2017

Thomas Jung

3

1 reference

11 September 2017

Rudolf Fuchs

4

1 reference

11 September 2017

Rick Aultman

5

1 reference

11 September 2017

Marlene Gyldmark

6

1 reference

11 September 2017

1 January 2006

1 reference

Clinical Drug Investigation

11 September 2017

1 reference

11 September 2017

26

1 reference

11 September 2017

6

1 reference

11 September 2017

329-340

1 reference

Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine

11 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00044011-200626060-00004

The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population

21 January 2018

1 reference

12 December 2020

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

12 December 2020

Influenza and influenza-like illness in general practice: drawing lessons for surveillance from a pilot study in Paris, France.

1 reference

12 December 2020

A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population

1 reference

12 December 2020

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

12 December 2020

A perspective on the significance of pandemic influenza

1 reference

12 December 2020

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

1 reference

12 December 2020

Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group

1 reference

12 December 2020

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

1 reference

12 December 2020

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

12 December 2020

Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir

1 reference

12 December 2020

Effect of influenza B virus infection on human performance

1 reference

12 December 2020

Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom

1 reference

12 December 2020

Early administration of oral oseltamivir increases the benefits of influenza treatment

1 reference

12 December 2020

Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection

1 reference

12 December 2020

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

1 reference

12 December 2020

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

1 reference

12 December 2020

Influenza vaccination among healthy employees: a cost-benefit analysis

1 reference

12 December 2020

The socio-economic burden of influenza

1 reference

12 December 2020

Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Successful treatment of naturally occurring influenza A/USSR/77 H1N1.

1 reference

12 December 2020

Acute respiratory illness in the community. Frequency of illness and the agents involved

1 reference

12 December 2020

10.2165/00044011-200626060-00004

Identifiers

DOI

1 reference

11 September 2017

1 reference